← Back to Search

Blood Transfusion

Whole Blood Transfusion for Malaria (PLATFORM Trial)

N/A

Recruiting

Research Sponsored by Johns Hopkins Bloomberg School of Public Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre- and post-transfusion, comparing baseline measurements to measurements taken 2 hours after transfusion completion and 24 hours later. for the control arm, measurements will be made at baseline and study hour 6 ±2 and 24 hours later

Awards & highlights

PLATFORM Trial Summary

This trial tests if whole blood transfusion can improve survival in children with severe malaria and low platelet count.

Who is the study for?

This trial is for children under 5 with severe malaria and low platelet count, living within a certain health clinic area. They must have a specific level of parasites in their blood and hemoglobin between certain values. Kids in foster care or planning to move out of the area can't join.Check my eligibility

What is being tested?

The study is testing if giving whole blood transfusions to kids with severe malaria helps them survive better. It's an open-label trial, meaning everyone knows who gets the transfusion, and it randomly decides who gets treated.See study design

What are the potential side effects?

While not specified here, whole blood transfusions may cause allergic reactions, fever, iron overload in long-term cases, lung injury from fluid overload (TACO), or infections.

PLATFORM Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre- and post-transfusion, comparing baseline measurements to measurements taken 2 hours after transfusion completion and 24 hours later. for the control arm, measurements will be made at baseline and study hour 6 ±2 and 24 hours later

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre- and post-transfusion, comparing baseline measurements to measurements taken 2 hours after transfusion completion and 24 hours later. for the control arm, measurements will be made at baseline and study hour 6 ±2 and 24 hours later

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre- and post-transfusion, comparing baseline measurements to measurements taken 2 hours after transfusion completion and 24 hours later. for the control arm, measurements will be made at baseline and study hour 6 ±2 and 24 hours later for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of all-cause mortality

Secondary outcome measures

Change in hemoglobin (Hb)

Change in platelet count

Change in white blood cell (WBC) count

+3 more

PLATFORM Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Whole blood transfusionExperimental Treatment1 Intervention

Whole blood transfusion x1 (20 mL/kg)

Group II: ControlActive Control1 Intervention

Standard-of-care

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Johns Hopkins Bloomberg School of Public HealthLead Sponsor

410 Previous Clinical Trials

2,106,798 Total Patients Enrolled

Johns Hopkins UniversityOTHER

2,266 Previous Clinical Trials

14,837,365 Total Patients Enrolled

Tropical Diseases Research CentreUNKNOWN

1 Previous Clinical Trials

182 Total Patients Enrolled

Media Library

Whole blood transfusion (Blood Transfusion) Clinical Trial Eligibility Overview. Trial Name: NCT05711485 — N/A

Low Platelet Count Research Study Groups: Whole blood transfusion, Control

Low Platelet Count Clinical Trial 2023: Whole blood transfusion Highlights & Side Effects. Trial Name: NCT05711485 — N/A

Whole blood transfusion (Blood Transfusion) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05711485 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this experiment accept individuals of advanced age as participants?

"This trial is specifically seeking patients between 6 and 59 months of age."

Answered by AI

Are there any current opportunities for enrolment in this clinical trial?

"The clinicaltrials.gov website reveals that this medical trial, initially put up on August 1st 2023 and most recently updated at the end of January 2023, is no longer recruiting patients; however there are 212 other studies actively seeking candidates."

Answered by AI

Do I satisfy the requirements to partake in this trial?

"This medical trial requires 132 participants who are afflicted by severe malaria and aged between 6 months to 5 years. The applicants must satisfy certain criteria such as a platelet count of 75,000/uL or lower, hemoglobin levels between 5-9 g/dL, P. falciparum parasitemia ≥500 parasites/uL according to WHO standards, residence within health clinic catchment area and an informed consent signature from the parent or legal guardian for its duration."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Platelet-Directed Whole Blood Transfusion Strategy for Malaria

2024. "Platelet-Directed Whole Blood Transfusion Strategy for Malaria". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05711485.

All > Thrombocytopenia > Malaria